相关实验视频
Updated: Jan 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
主动便calprotectin收集的影响在一个外展协议的生物原始性型结肠炎患者-型结肠炎临床外展 (UCCO)
Scott MacKay1, Denise Parsons1, Candace Hagerman2
1Division of Gastroenterology, University of Alberta, Edmonton, AB T6G 2X8, Canada.
一个主动的外展协议改善了先前没有生物治疗的患者的性结肠炎 (UC) 护理. 结合便calprotectin (FCP) 和临床标记物,可以改善UC的管理.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病研究研究
- 临床试验方法论 临床试验方法论
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,需要对患者进行持续监测.
- 在阿尔伯塔大学IBD病房试点开展了一项主动的外展协议,用于生物素朴的UC患者.
- 该研究评估了该协议对UC患者护理的影响.
研究的目的:
- 评估主动推广协议的有效性,以管理以前没有使用过生物药物的UC患者.
- 确定临床和生化评估是否可以改善UC护理.
- 确定UC管理变化的关键预测因素.
主要方法:
- 通过电话与长期缺乏随访的生物学先验UC患者进行了联系.
- 参与者填写了经过验证的问卷 (部分梅奥,萨瑟兰指数,MARS-5) 并提供了血液检查和便calprotectin (FCP) 样本.
- 胃肠道学家收到了结果,并完成了关于预期管理修改的调查.
主要成果:
- 该方案涉及81名患者,导致55.6%的管理变化,主要是加快后续或升级.
- 在6名患者中发现了活跃的发作,在17名患者中发现了无症状的炎症.
- 便calprotectin (FCP) 和萨瑟兰指数得分显著预测了UC管理升级.
- 胃肠道学家发现该方案在86.4%的病例中是有用的.
结论:
- 一次性主动推广计划可以增强对生物素素的UC患者的护理.
- 综合便calprotectin (FCP) 和临床标志物在监测生物-naiveUC是优化管理至关重要的.
- 该协议在识别需要加强UC护理的患者方面表现出实用性.
更多相关视频
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Ulcerative Colitis in IBD
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...